Supplement
Nefiracetam is a lab-made member of the racetam family, thought to influence how brain cells signal to one another. Research has focused on apathy in people with depression after a stroke, and a double-blind trial of 137 people found apathy improved, though the evidence is limited. That same trial saw no clear difference in depression symptoms, and as a single small study, it leaves much unanswered.
Sources: PMID 19622685
- Updated
- How we grade
- 1 study cited
- Best evidence
- Grade C
- Conditions studied
- 2
- Outcomes
- 5
- Graded outcomes
- 0021
Evidence by condition
- Strong
- Moderate
- Limited
- Very limited
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Apathy Small Improvement | Improves (the measure goes down) | Small effect | 1 study | 137 people | ||
Studies that measured apathy | ||||||
| Depression Symptoms No effect | NoneNo effect | 137 people | ||||
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Apathy Small Improvement | Improves (the measure goes down) | Small effect | 1 study | 137 people | ||
Studies that measured apathy | ||||||
| Depression Symptoms | Improves (the measure goes down) | 137 people | ||||
| Stroke Recovery | Improves (the measure goes up) | 137 people | ||||
Key findings
- ApathyImproves (the measure goes down)
- Depression Symptoms
Studies cited
1 study from PubMed